![Estimating progression-free survival in patients with glioblastoma using routinely collected data | Journal of Neuro-Oncology Estimating progression-free survival in patients with glioblastoma using routinely collected data | Journal of Neuro-Oncology](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs11060-017-2619-1/MediaObjects/11060_2017_2619_Fig1_HTML.gif)
Estimating progression-free survival in patients with glioblastoma using routinely collected data | Journal of Neuro-Oncology
![Study of NSCLC, melanoma outcomes points to surrogacy between real-world endpoints and clinical trial endpoints - The Cancer Letter Study of NSCLC, melanoma outcomes points to surrogacy between real-world endpoints and clinical trial endpoints - The Cancer Letter](https://cdn.cancerletter.com/media/2020/09/story2-2-2.jpg)
Study of NSCLC, melanoma outcomes points to surrogacy between real-world endpoints and clinical trial endpoints - The Cancer Letter
![Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive](https://archive.cancerworld.net/wp-content/uploads/2015/10/Correlation-by-itself-does-not-imply-surrogacy.jpg)
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
![The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40271-021-00552-w/MediaObjects/40271_2021_552_Fig1_HTML.png)
The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink
![Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-020-0805-y/MediaObjects/41416_2020_805_Fig1_HTML.png)
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer
![Progression-free survival. Progression-free survival was defined as the... | Download Scientific Diagram Progression-free survival. Progression-free survival was defined as the... | Download Scientific Diagram](https://www.researchgate.net/publication/303747050/figure/fig3/AS:383406182551553@1468422565156/Progression-free-survival-Progression-free-survival-was-defined-as-the-time-from-date-of.png)
Progression-free survival. Progression-free survival was defined as the... | Download Scientific Diagram
![Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-022-01845-z/MediaObjects/41416_2022_1845_Fig1_HTML.png)
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
![Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology](https://www.thelancet.com/cms/attachment/920222f6-291f-43c1-bae7-36f1bc4968b9/gr1.jpg)
Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology
![Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download](https://images.slideplayer.com/30/9505354/slides/slide_4.jpg)
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download
![Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology](https://www.thelancet.com/cms/attachment/f10fa33d-cf21-48d9-862f-0a70a29890a5/gr1_lrg.jpg)
Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology
![Definition of progression free survival and overall survival for the... | Download Scientific Diagram Definition of progression free survival and overall survival for the... | Download Scientific Diagram](https://www.researchgate.net/publication/265644752/figure/fig1/AS:269802786783234@1441337405030/Definition-of-progression-free-survival-and-overall-survival-for-the-Gold-standard-and_Q320.jpg)